Raymond James Reinstates Market Perform on Denali Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Danielle Brill has reinstated a Market Perform rating on Denali Therapeutics (NASDAQ:DNLI).
October 10, 2024 | 1:12 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Raymond James has reinstated a Market Perform rating on Denali Therapeutics, indicating a neutral stance on the stock's performance.
The reinstatement of a Market Perform rating by Raymond James suggests that the analyst sees no immediate catalysts for significant price movement in Denali Therapeutics. This neutral rating implies that the stock is expected to perform in line with the market.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100